Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

We conducted a phase 1 study using midostaurin (25 mg or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose limiting toxicities were observed. Two patients (22%) achi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Hematol
Auteurs principaux: Ramsingh, Giridharan, Westervelt, Peter, McBride, Ali, Stockerl-Goldstein, Keith, Vij, Ravi, Uy, Geoffrey, Cashen, Amanda, DiPersio, John F., Abboud, Camille N.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4406413/
https://ncbi.nlm.nih.gov/pubmed/24488798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-014-1503-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires